Overcoming Drug Resistance: The EGFR Enigma

EGFR square

Currently, anti-EGFR therapies are approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer, squamous cell carcinoma of the head and neck, pancreatic cancer, and colorectal cancer. Most patients receiving anti-EGFR therapies benefit from the treatment, but the challenge they face, as do patients receiving most other targeted therapies, is that their tumors ultimately develop drug resistance. So efforts are underway to develop newer anti-EGFR therapies that can circumvent resistance to existing EGFR inhibitors.

Read More

Eric Rubin, MD, Discusses How the AACR Contributes to Advances for Patients

AACR-FDA workshop on dose-finding of small molecule oncology drugs

AACR membership includes scientists and physicians from across the cancer research enterprise. Whether basic, translational, or clinical researchers, they all share the same goal: to make progress for patients. In this post, Eric Rubin, MD, deputy editor of Clinical Cancer Research, one of the AACR’s eight journals, shares his thoughts on the AACR’s role in developing breakthrough cancer treatments.

Read More

Kenneth C. Anderson, MD, Discusses How the AACR Benefits Clinicians

Chicago, IL - The AACR Annual Meeting 2012: Kenneth C. Anderson, M.D., speaks during the PAS Session: Publication Ethics: Be Aware or Beware at the American Association for Cancer Research Annual Meeting here today, Monday, April 2, 2012. More than 18,000 physicians, researchers, health care professionals, cancer survivors and patient advocates are expected to attend the meeting at McCormick Place. The Annual Meeting highlights the latest findings in all major areas of cancer research from basic through clinical and epidemiological studies. Date: Monday, April 2, 2012 Photo by © AACR/Phil McCarten 2012 Technical Questions: todd@toddbuchanan.com; Phone: 612-226-5154.

Over the years, clinical research has become an integral part of the American Association for Cancer Research’s meetings and journals. We asked physician-scientist Kenneth C. Anderson, MD, editor-in-chief of Clinical Cancer Research, one of the AACR’s eight journals, to share what the AACR means to him, where the organization is going, and why clinicians like him should be involved.

Read More

Mastering the Clinical Development of Personalized Cancer Medicines

nurse-giving-injection-web

A string of innovative clinical trials designed to accelerate the pace at which personalized cancer medicines are developed have been announced, and in some cases initiated, over the past few …

Read More

New Findings Open Doors for Rational Lung Cancer Treatment Strategies

ALK with crizotinib

In a study published Tuesday in the American Association for Cancer Research’s journal Clinical Cancer Research, researchers identified two novel mutations that cause resistance to alectinib, a drug that belongs …

Read More